Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 3: 559 - 567

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230208.002

Effects of Zhenggan Huayu decoction (正肝化瘀方) combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis

  • Wenlin CHEN ,
  • Fang LIANG ,
  • Yuncheng ZHANG ,
  • Jinzhen LV ,
  • Daguo YANG
Expand
  • 1 Department of Liver Diseases, Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen 518172, China
    2 Department of Liver Diseases, Shenzhen Third People's Hospital, Guangdong 518112, China

Accepted date: 2022-05-05

  Online published: 2023-02-08

Supported by

Shenzhen Science and Technology Plan Project: Study on the Mechanism of Zhenggan Huayu Decoction Regulating Intestinal Flora in Liver Fibrosis based on LPS-TRL4 Signal Pathway(JCYJ20180302150216419)

Fold

Abstract

OBJECTIVE: To evaluate the effects of Zhenggan Huayu decoction (正肝化瘀方, ZGHY) combined with entecavir (ETV) on the gut microbiota in patients with chronic hepatitis B (CHB) fibrosis.

METHODS: A total of 59 CHB-related fibrosis patients were enrolled and treated with ZGHY combined with ETV (ZGHY + ETV) and ETV alone. Fecal samples were collected from patients at weeks 0, 12, and 24 after treatment and gut microbiota were analyzed by 16S rRNA gene sequencing.

RESULTS: Compared to the ETV group, microbiota diversity in the ZGHY + ETV group was increased after 24 weeks. Some potentially pathogenic bacteria, including Fusobacteriaceae spp., Acidaminococcus spp., and Erysipelotrichaceae spp. were reduced in the ZGHY + ETV group, while Eubacteriaceae spp., Lactococcus spp., and several other beneficial bacteria were increased.

CONCLUSION: Decreases in pathogenic bacteria and increases in probiotics were not always observed in the Traditional Chinese Medicine (TCM) group (e.g., Rothia was abundant). As an adjuvant TCM formulation for ETV, ZGHY had a positive role in the treatment of CHB patients.

Key words： hepatitis B, chronic; fibrosis; RNA, ribosomal, 16S; Zhenggan Huayu decoction; entecavir; gut microbiota

Cite this article

Wenlin CHEN , Fang LIANG , Yuncheng ZHANG , Jinzhen LV , Daguo YANG . Effects of Zhenggan Huayu decoction (正肝化瘀方) combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis[J]. Journal of Traditional Chinese Medicine, 2023 , 43(3) : 559 -567 . DOI: 10.19852/j.cnki.jtcm.20230208.002

References

[1] Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev 2020; 33: e00046-19.
[2] Suhail M, Abdel-Hafiz H, Ali A, Fatima K, et al. Potential mechanisms of hepatitis B virus induced liver injury. World J Gastroenterol 2014; 20: 12462-72.
[3] Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B Infection: a review. JAMA 2018; 319: 1802-13.
[4] Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018; 392: 2313-24.
[5] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98.
[6] Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014; 20: 7312-24.
[7] Calvaruso V, Craxì A. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 219-30.
[8] Wang T, Jin W, Huang Q, et al. Clinical efficacy and safety of eight Traditional Chinese Medicine combined with entecavir in the treatment of chronic hepatitis B liver fibrosis in adults: a network Meta-analysis. Evid Based Complement Alternat Med: eCAM 2020; 2020: 7603410.
[9] Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing Meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2022; 76: 186-94.
[10] Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-6.
[11] Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL. Contemporary clinical research of Traditional Chinese Medicines for chronic hepatitis B in China: an analytical review. Hepatology 2010; 51: 690-8.
[12] Hu J, Teng J, Wang W, et al. Clinical efficacy and safety of Traditional Chinese Medicine Xiaoyao San in insomnia combined with anxiety. Medicine 2021; 100: e27608.
[13] Zhang DQ, Mu YP, Xu Y, Chen JM, Liu P, Liu W. Research progress in Chinese Medicine preparations for promoting blood circulation and removing blood stasis for cirrhotic patients with portal vein thrombosis following splenectomy. Chin J Integr Med 2020; 28: 855-863.
[14] Huang C, Shen D, Sun S, et al. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: protocol for a systematic review and Meta-analysis of randomized controlled trials and cohort studies. Medicine 2019; 98: e15297.
[15] Wang T, Zhou X, Liu H, et al. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: a systematic review and Meta-analysis. Phytother Res 2018; 32: 757-68.
[16] Li X, Zhou D, Chi X, et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial. Hepatol Int 2020; 14:985-96.
[17] Li X, Zhang L, Qiu M, et al. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. Trials 2020; 21: 708.
[18] Jones RM, Neish AS. Gut microbiota in intestinal and liver disease. Annu Rev Pathol 2021; 16: 251-75.
[19] Wang X, Chen L, Wang H, Cai W, Xie Q. Modulation of bile acid profile by gut microbiota in chronic hepatitis B. J Cell Mol Med 2020; 24: 2573-81.
[20] Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol 2019; 16: 235-46.
[21] Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021; 19: 55-71.
[22] Yang R, Xu Y, Dai Z, Lin X, Wang H. The immunologic role of gut microbiota in patients with chronic HBV infection. J Immunol Res 2018; 2018: 2361963.
[23] Zeng Y, Chen S, Fu Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 2020; 27: 143-55.
[24] Lv LJ, Li SH, Li SC, et al. Early-onset preeclampsia is associated with gut microbial alterations in antepartum and postpartum women. Front Cell Infect Microbiol 2019; 9: 224.
[25] Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 2019; 37: 852-7.
[26] Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 2013; 41: D590-6.
[27] Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol 2020; 38: 685-8.
[28] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 2019; 68: 1014-23.
[29] Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents 2020; 56: 106000.
[30] Compare D, Coccoli P, Rocco A, et al. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-6.
[31] Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018; 7: 11-20.
[32] Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382-92.
[33] Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940-7.
[34] Shek D, Chen D, Read SA, Ahlenstiel G. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett 2021; 510: 48-58.
[35] Roberti MP, Yonekura S, Duong CPM, et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat Med 2020; 26: 919-31.
[36] Kaakoush NO. Insights into the role of erysipelotrichaceae in the human host. Front Cell Infect Microbiol 2015; 5: 84.
[37] Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21: 11567-83.
[38] Qin F, Wu H, Li X, Han J. Correlation between changes in gut flora and serum inflammatory factors in children with noninfectious diarrhea. J Int Med Res 2020; 48: 300060519896154.
[39] Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-9.
[40] Maccioni L, Gao B, Leclercq S, et al. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut microbes 2020; 12: 1782157.
[41] Wang B, Zhang SQ, Dong JL, et al. Ambient temperature structures the gut microbiota of zebrafish to impact the response to radioactive pollution. Environ Pollut 2021; 293: 118539.
[42] Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc 2021; 80: 37-49.
[43] Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1-8.
[44] Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 2018; 174: 1406-23. e16.
Options
Outlines

/

〈 〉